
Drugs Approved for Type 2 Diabetes Treatment
The treatment of type 2 diabetes has been transformed in the past decade with the introduction of new medications, drug classes, and treatment approaches. These advances offer diabetics a wider range of combination therapies able to provide tighter glycemic control over the long term.
The approved medications are broken down by drug class, each of which offers different mechanisms of action.
DPP-4 Inhibitors
Dipeptidyl peptidase-4
(DPP-4) inhibitors work by blocking the DPP-4 enzyme which destroys the hormone incretin.
Incretins help the body produce more insulin when needed and reduce the amount of glucose being produced by the liver when it is not needed. There are currently five DPP-4 inhibitors approved by the U.S. Food and Drug Administration (FDA):
Galvus (vildagliptin)
Onglyza (saxagliptin)
Tradjenta (linagliptin)
Nesina (alogliptin)
Incretin Mimetics
As per their name, incretin mimetics
work by mimicking the action of incretins to stimulate the production of insulin. They also slow the rate of digestion so that glucose enters the blood more slowly.
There are five incretin mimetics currently approved by the FDA which are delivered by injection and used in people who have not been able to control their blood sugar with oral medications:
Byetta (exenatide)
Victoza (liraglutide)
Trulicity (dulaglutide)
Tanzeum (albiglutide)
Lyxumia (lixisenatide)
Also known as GLP-1 receptor agonists, the drugs are used in combination with oral medications and come in prefilled injector pens.
They are not insulin or to be used in place of insulin.
Selective Sodium-Glucose Transporter-2
Continue
reading